| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Human |
| Target | Ticagrelor, AR-C124910XX (the active metabolite)[1] |
| Clinical data | |
| Other names | PB2452, MEDI2452 |
| Routes of administration | Intravenous infusion |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem SID | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C2095H3240N560O674S12 |
| Molar mass | 47440.93 g·mol−1 |
Bentracimab is a monoclonal antibody medication which has been shown in phase one and two clinical trials to function as a reversal agent for the anti–blood clotting drug ticagrelor (which acts as a P2Y12 inhibitor and is sold under the brand name Brilinta among others).[2] It is under investigation for use in major, life-threatening bleeding in patients being treated with ticagrelor.[3][4] It is not commercially available.
See also
- Other reversal agents for antithrombotic drugs
References
- ↑ "Specialist Pharmacy Service: Bentracimab". National Health Service. 10 January 2021.
- ↑ "EU patients enrolled in REVERSE-IT trial of bentracimab for reversal of antiplatelet effects of ticagrelor". Cardiovascular News. 2021-01-29.
- ↑ Clinical trial number NCT04286438 for "A Phase 3, Multicenter, Open-Label, Single-Arm Study of Bentracimab (PB2452) in Ticagrelor-Treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT Trial)" at ClinicalTrials.gov
- ↑ Makhdoum A, Dhingra NK, Kirubaharan A, Eikelboom R, Luc J, Dagher O, et al. (August 2021). "Ticagrelor use and practice patterns among Canadian cardiac surgeons". Journal of Cardiac Surgery. 36 (8): 2793–2801. doi:10.1111/jocs.15636. PMID 34028081.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.